Free Newsletter
MediGene advances viral approach to treating cancer
Germany's MediGene grabbed the headlines at a conference in Switzerland recently with new efficacy data from a Phase I/II trial of a genetically engineered herpes virus designed to kill cancer cells. NV1020 was designed to replicate only in cancer cells, killing the host while leaving healthy tissue alone. In one advanced case where the cancer had spread to a variety of places in the body, the therapy--in combination with chemotherapy--almost eradicated several tumors in the liver area. That patient survived an additional 12 months. People with cancer that has spread to the liver rarely survive very long. These first human cases in the trial follow animal studies that demonstrated the approach was effective in treating liver cancer and colorectal cancer. The researchers also believe that this method of treatment would avoid many of the severe complications associated with treating cancer patients.
- see this release
- read the article from Fox News
Related Articles:
MediGene to buy UK's Avidex. Report
MediGene begins trial in RA. Report
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
